China's National Medical Products Administration (NMPA) has approved Hong Kong-based Harbour BioMed's Investigational New Drug (IND) application for HBM4003, the next generation anti-CTLA-4 antibody in combination with PD-1 antibody/chemotherapy intended for the treatment of patients with advanced NSCLC and solid tumours, it was reported on Thursday.
The study is to assess the safety, tolerability, PK/PD, and anti-tumour activity of the product in combination with PD-1 antibody, with or without chemotherapy, in subjects with advanced NSCLC and other solid tumours.
The product is the fully human anti-CTLA-4 monoclonal heavy chain only antibody generated from Harbour Mice. It has already received US FDA and China NMPA IND approvals of the mono therapy and another combination therapy in China. It has completed patient dosing in several patients in its ongoing phase I study in Australia.
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hikma Pharmaceuticals USA announces USD1bn of new US investment
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder